MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction CancerGlobeNewsWire • 10/25/19
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast CancerGlobeNewsWire • 10/22/19
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 CongressGlobeNewsWire • 09/30/19
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/01/19
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/02/19